Many thanks for your reply ChazzleDazzle I have

Many thanks for your reply ChazzleDazzle

I have always placed priority on protecting the formula for Leronlimab and I hope that with the loss of Nitya Ray, that it remains just as well protected.

With regards to the patents, I fall back to what Scott Kelly has said.

Quote:

---

We want to address questions on Patents. I want people to understand that we have a highly qualified duteek ?? firm that has handled our IP portfolio for many years. Since LRM is a biologic, it will receive 12 years of exclusivity if approved. The original patent composition of matter does expire in 2023 , but the Concentrated Protein Formulation does not expire until 2031, and this is what has been used in all our clinical studies . We will also pursue methods that use patents LRM in a novel way across many indications.

---

I got that from here:
https://www.reddit.com/r/LeronLimab_Times/com...;context=3

He says again:

Quote:

---

43:56 Christine: So do we have a filed patent for each indication we use LRM on or is 1 patent overreaching?

Scott Kelly: So again to emphasize, our protein concentration formula that has been used in all our clinical trials, lasts until 2031 . Now upon approval, biologics get 12 years of exclusivity , so we will continue to pursue methods of these patents which is essentially patents for LRM in various indications based on MOA.

---

That came from:
https://www.reddit.com/r/LeronLimab_Times/com...;context=3

The only problem really is that I placed so much emphasis on what Scott Kelly has said being that he is the CMO, and now his role has been removed from the Board of Directors replaced by Simes and Dunlap, I'm not too sure anymore how weighty to make his claims and assertions. He was friends with Nader and so was Ray.